MX2021010893A - Anticuerpo biespecifico enlazado especificamente a vegf y ang2. - Google Patents

Anticuerpo biespecifico enlazado especificamente a vegf y ang2.

Info

Publication number
MX2021010893A
MX2021010893A MX2021010893A MX2021010893A MX2021010893A MX 2021010893 A MX2021010893 A MX 2021010893A MX 2021010893 A MX2021010893 A MX 2021010893A MX 2021010893 A MX2021010893 A MX 2021010893A MX 2021010893 A MX2021010893 A MX 2021010893A
Authority
MX
Mexico
Prior art keywords
ang2
vegf
antibody
specifically bound
bispecific antibody
Prior art date
Application number
MX2021010893A
Other languages
English (en)
Inventor
Hua Ying
Weikang Tao
Hu Ge
Jinping Shi
Xiaoying Yang
Langyong Mao
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of MX2021010893A publication Critical patent/MX2021010893A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente divulgación proporciona un anticuerpo biespecífico enlazado específicamente a VEGF y ANG2, que comprende un anticuerpo anti-VEGF o un fragmento de unión a antígeno del mismo que se enlaza específicamente a VEGF, y un anticuerpo anti-ANG2 de dominio único que se enlaza específicamente a ANG2, en donde el anticuerpo anti-ANG2 de dominio único está conectado directa o indirectamente al anticuerpo anti-VEGF o un fragmento de unión a antígeno del mismo. La presente divulgación proporciona además un anticuerpo anti-ANG2 de dominio único y un fragmento de unión a antígeno del mismo, así como una preparación y aplicación de dicho anticuerpo.
MX2021010893A 2019-03-18 2020-03-17 Anticuerpo biespecifico enlazado especificamente a vegf y ang2. MX2021010893A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910204246 2019-03-18
PCT/CN2020/079690 WO2020187202A1 (zh) 2019-03-18 2020-03-17 特异性结合vegf和ang2的双特异性抗体

Publications (1)

Publication Number Publication Date
MX2021010893A true MX2021010893A (es) 2021-10-01

Family

ID=72519544

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021010893A MX2021010893A (es) 2019-03-18 2020-03-17 Anticuerpo biespecifico enlazado especificamente a vegf y ang2.

Country Status (11)

Country Link
US (1) US20220185875A1 (es)
EP (1) EP3943511A4 (es)
JP (1) JP2022526487A (es)
KR (1) KR20210141992A (es)
CN (1) CN112955473B (es)
AU (1) AU2020242704A1 (es)
BR (1) BR112021018451A2 (es)
CA (1) CA3133508A1 (es)
MX (1) MX2021010893A (es)
TW (1) TW202037610A (es)
WO (1) WO2020187202A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022183418A1 (zh) * 2021-03-04 2022-09-09 百奥泰生物制药股份有限公司 抗vegf抗体制剂
JP7220261B1 (ja) 2021-09-01 2023-02-09 レノボ・シンガポール・プライベート・リミテッド カバー部材の製造方法及び電子機器
AU2021463580A1 (en) * 2021-09-10 2024-04-11 Soter Biopharma Pte. Ltd. Anti-ang2 antibody, preparation method therefor, and application thereof
CN116265487A (zh) * 2021-12-16 2023-06-20 三优生物医药(上海)有限公司 抗ang2-vegf双特异性抗体及其用途
WO2024065268A1 (zh) * 2022-09-28 2024-04-04 科兴生物制药股份有限公司 能够识别ang-2的抗体或抗原结合片段和同时识别vegf和ang-2的双抗
CN117946262B (zh) * 2024-03-26 2024-05-28 北京纳百生物科技有限公司 一种阿维菌素单克隆抗体、试纸条及应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
DE69841815D1 (de) 1997-04-07 2010-09-16 Genentech Inc Anti-VEGF Antikörper
AU2007215013A1 (en) 2006-02-15 2007-08-23 Imclone Systems Incorporated Functional antibodies
AU2007256617A1 (en) 2006-06-06 2007-12-13 Genentech, Inc. Compositions and methods for modulating vascular development
ES2333935B1 (es) 2008-07-10 2010-11-26 Manuel Lido San Miguel Luminaria de diodos led con lente de distribucion luminica.
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
AR080794A1 (es) * 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
US9527925B2 (en) * 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
CN102250247B (zh) * 2011-06-15 2013-06-19 常州亚当生物技术有限公司 一种抗vegf/ang2双特异性抗体及其应用
MX350248B (es) * 2012-03-30 2017-08-31 Boehringer Ingelheim Int Moleculas de union a ang2.
WO2014009465A1 (en) * 2012-07-13 2014-01-16 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
PL3328886T3 (pl) * 2015-07-29 2021-02-08 Allergan, Inc. Przeciwciała ang-2 o wyłącznie ciężkim łańcuchu
CN109310756B (zh) * 2016-05-13 2022-06-28 奥美药业有限公司 新型血管生成素2，vegf双特异性拮抗剂
WO2018014260A1 (en) * 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
CA3034574A1 (en) * 2016-08-23 2018-03-01 Medimmune Limited Anti-vegf-a and anti-ang2 antibodies and uses thereof

Also Published As

Publication number Publication date
TW202037610A (zh) 2020-10-16
CN112955473B (zh) 2022-11-22
CN112955473A (zh) 2021-06-11
JP2022526487A (ja) 2022-05-25
US20220185875A1 (en) 2022-06-16
CA3133508A1 (en) 2020-09-24
WO2020187202A1 (zh) 2020-09-24
EP3943511A4 (en) 2023-03-08
KR20210141992A (ko) 2021-11-23
BR112021018451A2 (pt) 2021-11-23
EP3943511A1 (en) 2022-01-26
AU2020242704A1 (en) 2021-11-04

Similar Documents

Publication Publication Date Title
MX2021010893A (es) Anticuerpo biespecifico enlazado especificamente a vegf y ang2.
PH12019502282A1 (en) Bispecific antibodies specifically binding to pd1 and lag3
MX2020010382A (es) Anticuerpos biespecificos para pd1 y tim3.
MX2019012953A (es) Anticuerpo biespecifico contra ox40 y ctla-4.
MX2023003418A (es) Moleculas multiespecificas de union a antigenos y usos de estas.
MX2018008934A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
BR112017025080A2 (pt) composto conjugado de fármaco com anticorpo anti-cd123, composição conjugada de fármaco com anticorpo, método de tratamento de um paciente que tem um câncer que expressa cd123, composição farmacêutica, e, anticorpo intacto ou fragmento de ligação de antígeno
MX2013005847A (es) Proteinas de union a antigeno multiespecificas que eligen como blanco a hgf.
TN2019000161A1 (en) Anti-pd-1/anti-her2 natural antibody structure-like bispecific antibody of heterodimeric form and preparation thereof
EA201990672A1 (ru) Антитела, специфически связывающиеся с pd-1, и их функциональные фрагменты
TN2014000107A1 (en) Anti-aplhabetatcr antibody
MX352599B (es) Anticuerpos anti-receptor tipo proteina-tirosina-fosfatasa sigma humano.
BR112017019617A2 (pt) Anticorpo, composto conjugado anticorpo- fármaco anti-cd48, composição de conjugado anticorpo-fármaco, métodos para tratar um paciente com um câncer que expressa cd48, para produzir um anticorpo anti-cd48 e para produzir um conjugado anticorpo-fármaco anti-cd48, ácido nucléico isolado, vetor isolado, e, célula hospedeira isolada
WO2020051333A8 (en) Anti-avb8 antibodies and compositions and uses thereof
PH12020551661A1 (en) Anti-pd-l1 antibody and use thereof
MX2019011585A (es) Anticuerpos miltiespecificos estables.
EA201992316A1 (ru) Композиции и способы для диагностики рака предстательной железы
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof
MX2020009902A (es) Anticuerpos con especificidad dual para pd-l1 y pd-l2 humanos y metodos de uso de los mismos.
MX2023009584A (es) Anticuerpos monoclonales anti-chinches y metodos de elaboracion y usos de los mismos.
EA201791970A1 (ru) Способ лечения первичного склерозирующего холангита
EA201891529A1 (ru) Композиции и способы обнаружения и лечения рака яичников
PH12015501650A1 (en) Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof
SG11201810779PA (en) Method for screening antibody using patient-derived tumor spheroids
EA202091053A1 (ru) Модифицированные c- и ch1-домены